Currently, clinical trials are exploring the efficacy of MEK inhibitors, either alone or in combination with pan-RAF inhibitors, CDK4/6 inhibitors, or focal adhesion kinase inhibitors, for the management of metastatic NRAS-mutant melanoma [95,96,97]. This evidence concerns the gene CDK4 and melanoma.